Second Global Regulatory Filing for ABRAXANE in the Past Four Months LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABBI ABBI - Advanced Breast Biopsy Instrumentation), an integrated, global biopharmaceutical company, announced today that the Therapeutic Goods Admi...

LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced a licensing agreement with Biocon Limited, India's leading biotechnology company, for the commercialization of ABRAXANE([R]) (paclitaxel prote...

Oral Presentation of Interim Analysis of Randomized, Head-to-Head Phase II Study of ABRAXANE Versus Taxotere( )In First-line Metastatic Breast CancerPoster Presentations Highlight Treatment of Breast Cancer with ABRAXANE in Various Settings and Dose RegimensLOS ANG...

SCHAUMBURG, Ill. & LOS ANGELES -- American Pharmaceutical Partners, Inc. (NASDAQ:APPX):--Pre-clinical Dose-Ranging Study: Improved Activity of ABRAXANE(R) vs. Taxotere(R)--nab NAB - Nahj Al-Balaghah (Islam; speeches and letters by Ali ibn Abi Talib)NAB - Name an...

Tokyo, Japan, Nov 21, 2005 - (JCNN) - Taiho Pharmaceutical announced on November 16 that it has signed a licensing agreement with American BioScience for ABRAXANE, an anti-cancer agent. Under the agreement terms, Taiho will develop and sell the agent in Japan. ...

Wall Street got what it wanted--and then some. The proposed acquisition of Santa Monica-based American BioScience Inc. by its largest shareholder, American Pharmaceutical Partners Inc., should give the Schaumburg, Ill.-based public company the transparency tha...

INVESTORS who bought shares earlier this year in American Pharmaceutical Partners Inc., the genetic drug maker controlled by Los Angeles doctor Patrick Soon-Shiong, don't have much to feel good about these days. The stock, which hit a 52-week high of $49.19 on March...

Drug Approval: Abraxis BioScience Inc. said that the European Medicines Agency has accepted the company's application to market its Abraxane drug for the treatment of breast cancer. Abraxane was approved in the United States in 2005 and in Canada this June. The L...

LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that the Korean FDA (KFDA) has granted marketing approval for ABRAXANE([R])(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) f...

Findings Suggest ABRAXANE Avastin Combination Overcomes Newly Discovered Phenomenon of Reactionary Angiogenesis ...

Interim Data from Phase II Trial Presented at 44(th) Annual Meeting of the American Society of Clinical Oncology ...

LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that it intends to appeal the jury ruling in the U.S. District Court for the District of Delaware that Abraxis has infringed upon a patent owned by...

LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the establishment of a global leadership team with newly created positions that strengthen the company's international senior leadership and build a worldw...